Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Key Highlights
- ➤Five lorundrostat abstracts will be presented at AHA Hypertension Scientific Sessions 2026.
- ➤Explore-OSA oral presentation evaluates lorundrostat in moderate-to-severe OSA and hypertension.
- ➤Launch-HTN analysis examines blood pressure responders with lorundrostat in uncontrolled and resistant hypertension.
- ➤Lorundrostat is an investigational aldosterone synthase inhibitor targeting uncontrolled or resistant hypertension.
- ➤Mineralys (MLYS) has completed six late-stage lorundrostat clinical trials.
RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that five abstracts will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, taking place October 7-11 in Arlington, VA.
Title:Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Obstructive Sleep Apnea and Hypertension: Explore-OSA Randomized Crossover Trial
Get started
Create a free account to read the full story.